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Abstract
Cholinergic crisis triggered by inhibition of cholinesterases via organophosphorus
nerve agents (OP) and pesticides is treated with atropine and a reactivator of inhib-
ited cholinesterase, called oxime. Multiple in vitro and in vivo studies demonstrated
that this standard therapy may secure survival, but is insufficient in preventing
incapacitation and lacks efficacy against several nerve agents and pesticides. Over
the years, novel therapy approaches have been closely investigated with promising
candidates being non-oxime reactivators and scavengers based on enzymes (bioscav-
engers) or small molecules. The low efficacy and immunological compatibility are
main disadvantages of bioscavengers, thus the focus of the presented thesis is on a
small molecule scavenger and a non-oxime reactivator.
Detoxification of OP by cyclodextrins (CD), a macrocycle, was recognized early and
optimized by inserting a nucleophilic group at the rim of the CD cavity. But the
development of a more potent scavenger with a broad spectrum activity is closely
linked to gathering information about inclusion complexes in cyclodextrins and their
influencing factors. For that reason a structure-activity study with a 6-pyridinium
oximate substituted β-cyclodextrin and alkyl methylphosphonofluoridates (sarin
derivatives) was performed. Therefore, it can be concluded that the oxime substi-
tuted β-cyclodextrin better detoxifies sarin derivatives than native β-cyclodextrin,
conforming involvement of the nucleophilic group in OP degradation. Good inclusion
of OP in the CD cavity is correlated with a higher stability constant and improved
degradation. Data imply efficient detoxification of alkyl methylphosphonofluoridates,
thus the oxime substituent β-cyclodextrin is a promising small molecule scavenger
for poisoning with G-type nerve agents.
Another novel approach for the treatment of OP poisoning could be the use of
small molecules as non-oxime reactivators. The antimalarial drug amodiaquine
was identified as a promising candidate without further investigating its potential
against a broad range of OP. Therefore amodiaquine’s interaction with human acetyl-
cholinesterase (AChE) and butyrylcholinesterase (BChE) in presence or absence
of OP was investigated and revealed a reversible inhibition of cholinesterases by
amodiaquine and a mixed competitive-non-competitive inhibition type with AChE.
Amodiaquine inhibited AChE more potently than BChE, wherefore a dose escalation
was not possible. Reactivation of cyclosarin-, sarin-, and VX-inhibited cholinesterases
by amodiaquine occurred, whereas reactivation of tabun-inhibited cholinesterase was
insufficient. In a dynamic model, amodiaquine was administered prior to soman
poisoning, but no significant beneficial effect on cholinesterases or reactivation of
inhibited cholinesterases was observed. However, amodiaquine’s mode of action
in reactivating OP-inhibited cholinesterases is not fully understood, but research
efforts should continue in order to generate a more potent non-oxime reactivator. In
summary, small molecules as scavengers and non-oxime reactivators have a promising
potential as novel therapeutics for the treatment of OP poisoning. Still, further
investigations are necessary and should progress on existing experiences.
I
Zusammenfassung
Eine cholinerge Krise, die durch Cholinesterasehemmung auf Grund einer Vergif-
tung mit phosphororganischen Nervenkampfstoffen (OP) und Pestiziden ausgelöst
wird, wird mit Atropin, und einem Cholinesterase-Reaktivator, welcher als Oxim
bezeichnet wird, behandelt. Viele in vitro und in vivo Studien bestätigen, dass die-
se Standardtherapie das Überleben sichern kann, aber nur unzureichend vor den
Vergiftungssymptomen schützt und unwirksam bei einigen Nervenkampfstoffen und
Pestiziden ist. In den letzten Jahren wurden neue Therapieansätze eingehend un-
tersucht, wobei Nicht-Oxim Reaktivatoren und Scavenger, basierend auf Enzymen
(Bioscavenger) oder kleinen Molekülen („small molecule scavenger“) aussichtsreiche
Kandidaten sind. Die geringe Wirksamkeit und immunologische Verträglichkeit sind
die größten Nachteile von Bioscavengern, weshalb der Fokus in der vorliegenden
Arbeit auf einen small molecule scavenger und ein Nicht-Oxim Reaktivator liegt.
Frühzeitig wurde OP-Bindung und -Abbau durch Cyclodextrine (CD), einem Ma-
krozyklus, erkannt und durch das Einfügen einer nukleophilen Gruppe am Rand
des CD-Hohlraumes optimiert. Aber die Entwicklung von einem hoch wirksamen
Scavenger mit einem breiten Wirkungsspektrum ist eng mit der Gewinnung von
Informationen über Einschlusskomplexe in CD und deren Einflussfaktoren verbun-
den. Aus diesem Grund wurde eine Struktur-Aktivitätsuntersuchung mit einem
6-Pyridiniumoximat substituiertem β-CD und Alkylmethylfluorphosphonaten (Sarin-
Derivate) durchgeführt. Daraus ergab sich, dass das Oxim-substituierte β-CD die
Sarin-Derivate besser entgiftete als das native β-CD, wodurch die Beteiligung der
nukleophilen Gruppe am OP-Abbau bestätigt wurde. Ein guter Einschluss des OP in
den CD-Hohlraum korrelierte mit einer hohen Stabilitätskonstante und verbessertem
Abbau. Die Daten zeigen eine effiziente Entgiftung von Sarin-Derivaten an und dass
das Oxim-substituierte β-CD ein vielversprechender small molecule scavenger bei
Vergiftungen mit G-Kampfstoffen sein könnte.
Ein weiterer therapeutischer Ansatz bei OP-Vergiftungen kann der Einsatz von
kleinen Molekülen als sogenannte Nicht-Oxim Reaktivatoren sein. Das Antimalaria-
Medikament Amodiaquin wurde als ein vielversprechender Kandidat identifiziert,
ohne dessen Potenzial gegenüber einem breiten Spektrum von OP weiter zu untersu-
chen. Daher wurden Interaktionen zwischen Amodiaquin mit humaner Acetylcholin-
esterase (AChE) und Butyrylcholinesterase (BChE) in Gegenwart und Abwesenheit
von Nervenkampfstoffen untersucht und dabei festgestellt, dass Amodiaquin Cholines-
terasen reversibel hemmt und für die AChE wurde ein gemischter kompetitiv-nicht-
kompetitiver Hemmtyp identifiziert. Amodiaquin hemmte AChE stärker als BChE,
weshalb eine Dosissteigerung nicht möglich war. Reaktivierung von Cyclosarin-,
Sarin- und VX-gehemmter Cholinesterase durch Amodiaquin trat auf, wohingegen
die Reaktivierung von Tabun-gehemmter Cholinesterase unzureichend war. In einem
dynamischen Modell wurde Amodiaquin vor einer Somanvergiftung verabreicht, je-
doch konnte kein deutlicher Schutzeffekt mit Cholinesterasen oder Reaktivierung von
gehemmter Cholinesterase beobachtet werden. Obwohl der Wirkmechanismus von
Amodiaquin bei der Reaktivierung von OP-gehemmten Cholinesterasen nicht voll-
ständig verstanden wurde, sollte weiter geforscht werden, damit ein wirksamerer und
weniger toxischer Nicht-Oxim Reaktivator gefunden werden kann. Zusammenfassend
stellen kleine Moleküle als Scavenger und Nicht-Oxim Reaktivatoren einen potenziell
neuen Therapieansatz für die Behandlungen von OP-Vergiftungen dar. Dennoch sind
weitere Untersuchungen nötig und sollten auf gewonnenen Erfahrungen aufbauen.
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1 Introduction 1
1 Introduction
1.1 Organophosphorus compounds
Phosphorus in its inorganic form as phosphate is mostly non-toxic and essential for
all living organisms as scaffold of RNA and DNA, cellular energy balance adenosine
triphosphate, component of cell membranes in form of phospholipids, and regulating
cellular processes by activation or inactivation via phosphorylation. Likewise, organic
forms of phosphorus as phosphate esters or also referred to as organophosphates
and organophosphorus compounds, have a wide field of application (e. g. flame
resistant oils, flame retardants, plasticizers, extreme pressure additives, and pes-
ticides). However, organophosphates can be highly toxic to organisms, which is
an advantage in pest control as pesticides, but also causes hundred thousands of
accidental or voluntary poisoning and human fatalities every year [32, 38]. The
advancement of more potent pesticides led to the discovery of organophosphorus
nerve agents (OP), a subclass of chemical warfare agents, by Gerhard Schrader in the
mid-1930s [75]. Nerve agents are divided into two main groups: G- and V-type nerve
agents. Properties of G-type nerve agents (“G” is the abbreviation for Germany)
include higher vapor pressure, lower hydrolytic stability, and persistency than V-type
nerve agents (for “V” various meanings are possible, like venomous, vicious, and
victorious). Cyclosarin (GF), sarin (GB), soman (GD), and tabun (GA) are typical
representatives of G-agents (Fig. 1.1). VX is the best-known V-type nerve agent and
was discovered by British and Swedish scientists in the mid-1950s [78, 80].
Figure 1.1: Structures of organophosphorus nerve agents and a pesticide.
The use of OP in international armed conflicts was interdicted by the Hague Con-
ventions (1899 and 1907) and Geneva Protocol (1925) with enhancement by the
Chemical Weapons Convention (1993), which additionally prohibits the production
and stockpiling of chemical weapons [68]. Despite these treaties, OP still constitute
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a threat to humans, e.g. deployment of tabun and sarin at the Kurdish city Halabja
in the Iraq-Iran War, unintended exposure to cyclosarin and sarin of allied troops
while dismantling Khamisiyah ammunition storage facility after the Gulf War, usage
of sarin in terrorist attacks and VX in an assassination by the Aum Shinrikyo sect in
the mid-1990s in Japan, and lately deployment of sarin in Syria affirm importance of
effective medical countermeasures [12, 26, 53, 62, 65, 85].
1.2 Mode of action of organophosphorus compounds
OP’ acute toxicity is based on irreversible inhibition of acetylcholinesterase (AChE,
EC 1.1.1.7) by phosphylation of a serine hydroxyl group at its active site resulting in an
inactive enzyme [1, 54, 81]. Consequential a surplus of neurotransmitter acetylcholine
at synaptic clefts of peripheral and central nervous system with overstimulation
of muscarinic and nicotinic acetylcholine receptors is triggering a cholinergic crisis,
which eventually causes respiratory arrest and finally death [31, 37, 51, 66, 98].
Anticholinesterase activity of OP depends on electrophilicity of the phosphorus,
which is increased by greater electron-withdrawing capacity of the nerve agent’s
substituent and supports the nucleophilic attack of catalytic serine which leads
to phosphylated AChE [27, 29]. The stability of phosphyl-AChE-complex is more
pronounced than the physiological serine-acetate intermediate and reflected in a
half-life of hours to days [39]. Spontaneous hydrolysis is incapable of restoring AChE’s
complete functionality whereas stronger nucleophiles, termed reactivators or oximes,
can remove the phosphyl moiety via nucleophilic attack and reactivate the enzyme
(Fig. 1.2) [36, 89]. Efficacy of reactivation is influenced by the enzyme’s species,
structure of phosphyl moiety, structure of oxime, and a post-inhibitory process of
phosphyl-AChE-complex [1, 52]. Dealkylation of an alkoxy group of phosphylated
AChE through the release of an alcohol is called “aging”, which is resistant to oxime
reactivation [1, 5, 7, 9, 36, 61]. Aging of soman can occur in a few minutes, tabun in
hours, and pesticides such as paraoxon take up to days, therefore a timely provision
of medical countermeasurements is decisive [1, 79].
Figure 1.2: Processes of phosphorylation, aging, and reactivation between an
organophosphorus compound (X stands for the leaving group) and a
cholinesterase (E).
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Nerve agents are present in form of a racemic mixture; therefore at least two different
stereoisomers exist. The enantiomers of nerve agents have significant discrepancies
in their toxicity, stability, and biological activity. (-)P-enantiomers of soman, sarin,
cyclosarin, tabun, and VX exhibit a higher inhibitory potency with AChE compared
to their corresponding (+)P-enantiomer [8, 21, 71, 82].
1.3 Therapy
Treatment of OP-poisoned patients currently consists of a concomitant administration
of an oxime such as obidoxime, pralidoxime (2-PAM) or HI-6, and an antimuscarinic
drug, e.g. atropine, often supplementd by an anticonvulsant [17, 28, 87]. The
peripheral muscarinic symptoms, like sweating, salivation, miosis, bradycardia, and
bronchorrhea are antagonized by atropine [33, 76]. Apart of activating muscarinic
acetylcholine receptors, cholinergic crisis also triggers nicotinic acetylcholine receptors
causing muscle fasciculation, muscle dysfunction, and respiratory depression [39].
Reactivation of OP-inhibited AChE via dephosphorylation by oximes can indirectly
assist in restoring the cholinergic system [36]. However, the inevitably formed
phosphylated oximes are highly reactive and may re-inhibit reactivated AChE [2, 46].
Efficacy of oximes is time-sensitive and inoperative in case of aged AChE. Hence,
rapid oxime administration is crucial, otherwise solely long-lasting de novo synthesis
can regain recovery of AChE. Clinically established oximes do not cover the broad
range of OP and hardly penetrate the blood-brain barrier [20, 28, 50, 55, 95, 96]. The
current treatment ensures survival, but prevention of behavioral incapacitation or
neurocognitive deficits is insufficient [59]. Despite 60 years of research and synthesis
of thousands of reactivators, no satisfying oxime was discovered emphasizing the
need for alternative approaches and more efficient countermeasures.
1.4 Alternative approaches
1.4.1 Bioscavenger
Systemic detoxification of OP by bioscavengers before target tissues are affected
is a more auspicious approach [18, 24, 74]. Apart from AChE, B-esterases such
as butyrylcholinesterase (BChE, EC 3.1.1.8), carboxylesterases (EC 3.1.1.1), and
neuropathy target esterase (EC 3.1.1.5) are inhibited irreversibly by OP. Consequently,
by binding OP in an 1:1 molar ratio B-esterases serve as stoichiometric scavengers,
thus reducing the toxic body load [15, 48, 64, 90]. Human BChE is the best
developed scavenger and showed efficacy in numerous studies [18, 63, 73]. Nevertheless,
detoxification of 2 x LD50 soman would require 200 mg of BChE, being challenging to
produce, finance, and administer without interfering in metabolic and immunologic
processes in the body [3, 57]. The combination of a stoichiometric bioscavenger (e.g.
AChE or BChE) and an oxime, constantly reactivating the phosphorylated scavenger,
is termed “pseudo-catalytic” bioscavenger [4, 44, 45, 70]. Recently, the new designed
slow aging AChE mutant Y337A/F338A and oxime RS-170B showed promising
performance [43]. Catalytic bioscavengers based on OP-hydrolyzing enzymes could
overcome previously mentioned limitations. A single molecule of a highly active
catalytic bioscavenger can detoxify theoretically indefinite OP molecules. Existing
wild-type enzymes, like human paraoxonase (PON1, EC 3.1.8.1), phosphotriesterase
(PTE, EC 3.1.8.1), and diisopropyl fluorophosphatase (DFPase, EC 3.1.8.2) perform
with a low catalytic efficacy towards OP and prefer hydrolysis of the less toxic
(+)P-enantiomers [60, 64, 84, 99]. Theoretical calculations indicate that a minimal
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catalytic efficacy (kcat/KM of >107 M-1 min-1) is required to sufficiently detoxify
OP at compatible enzyme doses [3, 72]. With a prudential approach and protein
engineering, PON1 mutants and PTE mutants with adequate catalytic efficacy and
stereoselectivity for toxic OP enantiomers were produced [19, 30, 42]. In vivo studies
with PON1 mutant IIG1 against 2 x LD50 cyclosarin s.c. and PTE mutant C23
against 2 x LD50 VX s.c. exhibited clearly the potential of catalytic bioscavengers
[91, 92]. However, as evaluated by Worek et al. (2016) the bioscavengers’ plasma
concentration was insufficient in preventing passage of OP into tissues resulting in
inhibited brain AChE activity [97]. As remedy, a higher catalytic efficacy (> 5 x 107
M-1 min-1) of scavengers is pursued in consideration of minimal extracorporeal load
and reasonable detoxification to exposure of multiple OP LD50 [97]. Still, research
needs to continue to descry an ideal catalytic bioscavenger, which is highly efficient,
detoxifies a broad spectrum of OP, producible in large quantities, stabile at long
storage, immunologically compatible to humans, and has a prolonged circulation
time [56, 57, 83].
1.4.2 Small molecule scavenger
Insufficiency of standard OP therapy and major limitations of bioscavengers promoted
the investigation of alternative approaches such as small molecule scavengers. Syn-
thetic compounds are considered regarding their potential to detoxify OP via binding
or hydrolysis. As a ring-shaped macrocycle consisting of six (α-), seven (β-) or eight
(γ-) α-1,4-glycopyranoside units, cyclodextrins (CD) are due to their capability of
binding organic substances in host-guest interactions favorable candidates (Fig. 1.3)
[25, 35]. Characterization of CD include low toxicity, wide application in many fields,
and clinical use [34, 40, 49, 69, 77]. Degradation of sarin, soman, and tabun by
native CD was observed by multiple studies [22, 23, 35]. Stereospecific degradation
was noted being in accordance with previous studies [22, 86].
Figure 1.3: Structures of small molecules amodiaquine and β-cyclodextrin.
Superior efficacy was achieved by addition of oxime or iodosobenzoate substituents to
CD cavity [47, 58, 88, 100]. A CD derivative with a pyridinium oximate in 6-position
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detoxified cyclosarin rapidly in vitro [100]. The arrangement of a hydroxamic acid
instead of an oxime at the cavity resulted in improved tabun decomposition, whereby
no influence of the CD ring and no stereospecificity existed [13]. Covalent modification
of CD with OP revealed a stoichiometric mode of action [14, 22]. Nevertheless,
prophylactic administration of a functionalized CD against cyclosarin ensured survival
and prevented systemic toxicity in anesthetized guinea pigs, confirming that OP
detoxification of small molecule scavengers is promising [93]. Unfortunately, so far
identification of a small molecule scavenger for broad spectrum OP degradation
failed.
1.4.3 Non-oxime reactivators
Instead of acting as a scavenger, small molecules can also serve as reactivators. Due
to the positive charge of the pyridinium moiety in clinically used oximes passage
through the blood-brain barrier and reactivation of OP-inhibited brain AChE is hardly
possible. Although a few blood-brain barrier penetrable oximes were discovered, none
showed sufficient efficacy [6, 67, 94]. As a novel concept, Bhattacharjee et al. (2012)
searched for non-oxime reactivators by virtually screening databases with an in silico
pharmacophore modeling [10]. Amongst twelve potent non-oxime reactivators, a
benzenesulfonamide derivate was as efficient as 2-PAM in preventing central nervous
system damage in vivo in DFP-inhibited guinea pigs [11]. Additional in silico
screenings revealed that the antimalarial drug amodiaquine might be an auspicious
candidate because it can reactivate PXE-inhibited AChE (Fig. 1.3) [41]. In further
investigations, mannich phenols in particular 4-amino-2-(diethylaminomethyl)phenol
(ADOC) were accounted for reactivation of PXE-inhibited AChE. Recently, ADOC
and related compounds were tested regarding their reactivation potential in vitro
and in vivo, but failed expectations [16]. Unfortunately, additional investigations
regarding amodiaquine’s potential were neglected.
1.5 Objectives of the presented thesis
Despite intensified research for decades, major drawbacks in the standard treatment
of OP poisoning could not be overcome, hence novel therapeutic approaches based
on bioscavengers or small molecule scavengers are currently closely investigated. The
presented thesis focuses on small molecules as scavengers or non-oxime reactivators
and their potential as therapeutics in OP poisoning.
For developing a scavenger with the potential to detoxify a broad spectrum of OP
more rapidly, data about preferred conditions for complex formation and desirable
structure of guests is needed. Therefore, a structure-activity study with a functional-
ized CD and various alkoxy residues of methylphosphonofluoridates (sarin derivatives)
was conducted, specified in chapter 2.1 (first publication).
Additionally, another small molecule, the antimalarial drug amodiaquine, was investi-
gated for its ability to detoxify OP, but failed expectations. However, reactivation of
OP-inhibited cholinesterases by amodiaquine was observed. Thus, amodiaquine was
further characterized by focusing on interactions between amodiaquine and human
cholinesterases (AChE and BChE) with different OP and relating data towards
reactivation potential, efficacy, and treatment options, which give a new insight in
OP therapy and is dealt with in chapter 2.2 (second publication).
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2 Publications
2.1 Detoxification of alkyl methylphosphonofluoridates by
an oxime-substituted β-cyclodextrin - An in vitro
structure-activity study
A. Bierwisch, M. Zengerle, H. Thiermann, S. Kubik, F. Worek, Toxicology Letters
2014, 224, 209-214.
Reproduced by permission of Elsevier.
The concomitant treatment of OP poisoning with atropine and an oxime has many
limitations. Numerous attempts were undertaken to prevent OP from exerting their
acute toxicity and neuronal malfunction without a breakthrough. Besides bioscav-
engers, small molecule scavengers are most widely studied towards their ability to
detoxify OP. Within a collaboration between the TU Kaiserslautern and the Bun-
deswehr Institute of Pharmacology and Toxicology a diversity of cyclodextrins were
synthesized in Kaiserslautern and tested for their efficacy to bind or degrade OP in
München. A small molecule scavenger in form of a β-cyclodextrin bearing a nucle-
ophilic oximate group in 6-position showed high efficiency in cyclosarin detoxification
in vitro and in vivo [93, 100].
Nevertheless, a small molecule scavenger detoxifying a broad range of OP is prefer-
able. To develop the desired scavenger, detailed information about formation of
inclusion complexes between β-cyclodextrin and OP is essential. Therefore the
6-pyridinium oximate substituted β-cyclodextrin was extensively tested in vitro with
a broad range of methylphosphonofluoridates (sarin derivatives) varying in alkoxy
residue to determine structure-activity relationships. By applying a modified Ellman
assay, detoxification kinetics were determined spectrophotometrically. Degradation of
alkyl methylphosphonofluoridates was significantly better with the oxime substituted
β-cyclodextrin than native β-cyclodextrin, thereby conforming the essential role of
the nucleophilic group by OP degradation. An increased detoxification rate by the
substituted β-cyclodextrin was achieved with bulkier alkyl methylphosphonofluo-
ridates (publication 2.1, Table 2) iso-pentylsarin (kdetox = 118.5 ± 8.6 x 10-2 M-1
min-1), except for soman (kdetox = 1.0 ± 0.1 x 10-2 M-1 min-1). This led to the thesis
that a faster OP degradation is accompanied by a more stable complex formation
between substituted β-cyclodextrin and sarin derivatives. Data from a previous
study, in which stability constants of complex formation between β-cyclodextrin
and alcohol residue of OP were correlated, supported this hypothesis (publication
2.1, Table 2). Despite the similar structure to sarin, the nerve agent soman was
degraded significantly slower. Steric hindrance and increased existence of more toxic
and stabile (-)P-enantiomers of soman could be the reason for low detoxification of
this phosphonate by the oxime substituted β-cyclodextrin.
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a  b  s  t  r  a  c  t
Detoxiﬁcation  rates  of a series  of alkyl  methylphosphonoﬂuoridates  by an oxime-substituted  -
cyclodextrin  (-CD)  were  assessed  quantitatively  by  using  an  AChE  inhibition  assay.  The  cyclodextrin
(CD)  derivative  was identiﬁed  in  previous  work  as  a  highly  active  cyclosarin  scavenger.  Here, a
structure–activity  relationship  was  established  by  investigating  the  effect  of  this  CD  on  the  detoxiﬁcation
of  sarin  derivatives  differing  in the  structure  of the  alkoxy  residue.  The  results  show  that  detoxiﬁcation
rates  correlate  with  the  steric  bulk  and  chain  length  of  the  alkoxy  group  in the  organophosphonate  (OP).
OPs  with  larger,  more  bulky  residues  are  detoxiﬁed  more  rapidly, with  the  exception  of  soman,  which
is bearing  a  pinacolyloxy  side  chain.  In  addition,  the  substituted  CD  was  in every  case  more  active  than
unsubstituted,  native  -CD  with  up  to a 400-fold  difference.  Comparing  the  kinetic  results  obtained  with
the  known  thermodynamic  stabilities  of  related  -CD  complexes  indicate  that  detoxiﬁcation  rates  gen-
erally  increase  when  the  alkoxy  residue  on the  OP  is  exchanged  by  a residue,  which  forms  a  more  stable
complex  with  -CD.  This  correlation  lends  support  to  the  proposed  mode  of  action  of  the  substituted  CD,
involving  initial  complexation  of  the OP  followed  by  reaction  between  the  CD  and  the  OP.  The  moderate
to  high  efﬁcacy  on  the  detoxiﬁcation  of  sarin  derivatives  suggests  the  potential  applicability  of  this  CD  as
a small  molecule  scavenger  for  G-type  nerve  agents.
© 2013 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Every year 2–5 million people suffer from poisonings by pes-
ticides (accidental or suicidal) and up to 220,000 fatal cases
are estimated (Karalliedde and Szinicz, 2001). Pesticides are
a heterogeneous group of synthetic chemicals that include
organophosphorous compounds (OP) whose toxicity is due to the
covalent modiﬁcation and the resulting inhibition of the enzyme
acetylcholinesterase (AChE) (Taylor et al., 1995). AChE inhibi-
tion causes accumulation of the neurotransmitter acetylcholine
∗ Corresponding author. Tel.: +49 6312052479.
E-mail address: kubik@chemie.uni-kl.de (S. Kubik).
leading to disturbance of numerous body functions and eventually
to death due to respiratory arrest. Standard treatment of OP poi-
soning includes an anti-muscarinic compound, e.g. atropine, and
an oxime as AChE reactivator (Wiener and Hoffman, 2004). How-
ever, numerous limitations are associated with standard treatment
protocols. Antimuscarinic drugs do not counteract OP effects at
nicotinic receptors, for example. Moreover, oximes hardly cross the
blood–brain-barrier (Eyer and Worek, 2007; Aurbek et al., 2009)
and are generally insufﬁcient in reactivating AChE inhibited by cer-
tain nerve agents, e.g. soman and tabun (Eyer and Worek, 2007;
Worek et al., 2004). Also reactivation by oximes of inhibited AChE
containing an aged OP residue resulting from hydrolysis of an
alkoxy residue on the phosphorus atom is not feasible (Aldridge
and Reiner, 1972; Worek et al., 1996). Finally, treatment of
0378-4274/$ – see front matter ©  2013 Elsevier Ireland Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.toxlet.2013.10.024
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Fig. 1. Chemical structures of -CD and 6-OxP-CD.
poisonings with persistent nerve agents such as VX that are only
slowly cleared from the organism is particularly difﬁcult (Reiter
et al., 2008, 2011; Tenberken et al., 2010). In order to overcome
these limitations, new therapeutic approaches are urgently needed.
One research effort is directed at the development of stoichiomet-
ric or catalytic enzymes that can act as scavengers by binding or
degrading OPs in vivo prior to the appearance of any toxic effects
(Masson and Rochu, 2009). Synthetic compounds, so-called small
molecule scavengers, can serve similar purposes.
Promising lead structures for the development of small
molecule scavengers are cyclodextrins (CDs; Fig. 1), cyclic oligosac-
charides containing glycopyranose subunits linked by (1–4)
glycosidic linkages. Negligible toxicity and the relative ease with
which CDs can be structurally modiﬁed led to application of this
class of compounds in many different areas (Szejtli, 1998). A char-
acteristic feature of CDs is their ability to include small hydrophobic
compounds in the apolar interior of the macrocyclic cavity. Stabil-
ity of the complexes formed depends on ring size of the CD and on
the structure of the substrate. In general, substrates that efﬁciently
occupy the available space of the CD cavity are bound best. In the
case of the seven-membered -cyclodextrin (-CD), for example,
adamantane derivatives are very good substrates (Rekharsky and
Inoue, 1998). Complex stability is determined by a combination of
intermolecular interactions of which the most important are van-
der-Waals interactions (Bergeron et al., 1978), hydrogen bonding
(Tabushi et al., 1978), dipole–dipole interactions (Gelb et al., 1981;
Bergeron et al., 1977), and the hydrophobic effect (Connors, 1997).
Several studies have shown that native CDs can also degrade the
nerve agents soman and sarin (Hennrich and Cramer, 1965; Van
Hooidonk and Groos, 1970; Desiré and Saint-André, 1987). Degra-
dation efﬁciency could be improved by arranging functional groups
around the CD cavity that actively participate in the reaction. Exam-
ples include functionalization of -CD with 2-iodosobenzoates
or oximes, which afforded scavengers for cyclosarin, tabun, or
paraoxon (Masurier et al., 2005; Wille et al., 2009; Le Provost et al.,
2011; Zengerle et al., 2011). Zengerle et al. (2011) showed that
-CD derivative 6-OxP-CD (Fig. 1) with a pyridinium oximate in 6-
position of one glucose unit detoxiﬁes the toxic (−)-enantiomer of
cyclosarin within seconds and the less toxic (+)-enantiomer with a
half-time of 43 s under appropriate conditions. However, the same
CD had only a small effect on tabun detoxiﬁcation (Brandhuber
et al., 2012).
In order to investigate whether detoxiﬁcation activity of 6-
OxP-CD is limited to cyclosarin or if this compound is able to
detoxify other alkyl methylphosphonoﬂuoridates with similar efﬁ-
ciency, rates of 6-OxP-CD-mediated detoxiﬁcation of a series of
sarin derivatives differing in the alcohol component (Fig. 2) were
assessed by using an enzymatic in vitro assay. These measurements
allowed establishing a structure–activity relationship demonstrat-
ing that sarin derivatives with larger, bulky alkyl substituents that
presumably interact with 6-OxP-CD more strongly are detoxiﬁed
more rapidly than OPs with small alkyl residues.
2. Materials and methods
2.1. Materials
Acetylthiocholine iodide (ATCh), -cyclodextrin, 5,5′-dithiobis-(2-nitrobenzoic
acid) (DTNB) and tris(hydroxymethyl)aminomethane (TRIS) were obtained from
Sigma–Aldrich (Taufkirchen, Germany). Disodium hydrogenphosphate dihydrate,
potassium dihydrogenphosphate, and hydrochloric acid were purchased from
Roth (Karlsruhe, Germany). Sarin, cyclosarin, soman, ethylsarin, n-propylsarin,
iso-butylsarin, n-butylsarin, iso-pentylsarin, n-pentylsarin, neo-pentylsarin and sec-
pentylsarin (Fig. 2; >95% by GC–MS, 1H NMR  and 31P NMR) were made available
by  the German Ministry of Defence (Bonn, Germany). 6-OxP-CD was  synthesized
according to Zengerle et al. (2011). All other chemicals were purchased from Merck
Eurolab (Darmstadt, Germany).
Stock solutions of sarin, soman, cyclosarin (0.1%, v/v), and sarin analogs (1%, v/v)
were prepared in acetonitrile, stored at room temperature, and diluted appropriately
with Tris–HCl buffer (0.1 M,  pH 7.4) just before use. CD stock solutions (10 mM)  were
prepared daily in Tris–HCl buffer and diluted as required with Tris–HCl buffer prior
to  use.
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Fig. 2. Chemical structures of the alkyl methylphosphonoﬂuoridates tested.
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Hemoglobin-free human erythrocyte ghosts served as AChE source and were
prepared according to Dodge et al. (1963) with minor modiﬁcations (Worek et al.,
2002). Brieﬂy, heparinized human whole blood was centrifuged (3000 × g, 10 min)
for  plasma removal. The erythrocytes were washed three times with two vol-
umes of phosphate buffer (0.1 M,  pH 7.4). To facilitate hemolysis, the packed
erythrocytes were diluted in 20 volumes of hypotonic phosphate buffer (6.7 mM,
pH  7.4) and centrifuged at 50,000 × g (30 min, 4 ◦C). After two  additional wash-
ing  cycles the pellet was re-suspended in phosphate buffer (0.1 M,  pH 7.4) and
the initial AChE activity was adjusted. Aliquots of the erythrocyte ghosts were
stored at −80 ◦C. Prior to use, thawed ghosts were homogenized on ice with
Sonoplus HD 2070 ultrasonic homogenator (Bandelin electronic, Berlin, Germany)
twice for 5 s with a 20 s interval to achieve a homogenous matrix for kinetic
studies.
2.2. AChE assay
AChE activities were determined spectrophotometrically (UV mc  2, SAFAS,
Monaco) with a modiﬁed Ellman assay at 412 nm (Ellman et al., 1961; Eyer et al.,
2003; Worek et al., 1999). Polystyrol cuvettes (3.18 mL)  contained ATCh (50 L,
0.45 mM)  as substrate and DTNB (100 L, 0.3 mM)  as a chromogen in 0.1 M Tris–HCl
buffer (3.0 mL). All experiments were performed at 37 ◦C and the given concentra-
tions refer to ﬁnal concentrations.
2.3. Determination of detoxiﬁcation constants
Detoxiﬁcation kinetics of the different OPs by -CD or 6-OxP-CD were inves-
tigated by an AChE inhibition assay (Wille et al., 2013). 50 L -CD or 6-OxP-CD
(0.1 M Tris–HCl buffer, pH 7.4) were mixed with 10 L OP (0.1 M Tris–HCl buffer)
and 140 L Tris–HCl (0.1 M,  pH 7.4; t = 0). The resulting CD concentrations were
2.5 mM,  except for cyclosarin and pentylsarin analogs (0.5 mM)  and the ﬁnal OP
concentrations were 50 mM (sarin, soman, cyclosarin), 30 mM (ethylsarin), 6 mM
(n-propylsarin, n-butylsarin) and 5 mM for the remaining OPs. After speciﬁed
time intervals, 20 L aliquots were transferred to 37 ◦C thermostated cuvettes for
recording the inhibition of AChE activity. Corresponding experiments with OPs in
Tris–HCl buffer were performed to determine the spontaneous hydrolysis kinet-
ics.
The  recorded inhibition curves for each sample were analyzed by non-
linear regression analysis to calculate ﬁrst-order inhibition rate constants kobs
(Fig. 3A; Aurbek et al., 2006). These values were plotted vs. the time of incu-
bation to which they correspond. First-order detoxiﬁcation constants k1 were
then obtained by ﬁtting the resulting decay curves (Fig. 3B and C) and correcting
for  spontaneous hydrolysis of the corresponding OP. Finally, pseudo second-
order detoxiﬁcation constants kdetox were calculated on the basis of Eq. (1).
kdetox =
k1
c(CD)
(1)
2.4. Data analysis
Kinetic constants were calculated from the experimental data by non-linear
regression analysis using Prism 5.04 (GraphPad Software, San Diego, CA, USA). All
experiments were performed in duplicate.
3. Results
Incubation of -CD or 6-OxP-CD with all sarin derivatives
considered in this study resulted in a time-dependent mono-
exponential decrease of the inhibition potency of the solutions
toward human AChE (Fig. 3 and Table 1). From these data,
ﬁrst-order detoxiﬁcation constants could be calculated. These
detoxiﬁcation rate constants were corrected by the rates of spon-
taneous hydrolysis of the respective OP, which ranged between
0.010 min−1 (GB, GD, GF) and 0.034 min−1 (ethylsarin), to yield
k1. The k1 values thus reﬂect the extent to which detoxiﬁcation
rate is faster than spontaneous hydrolysis of the respective OP.
Due to differences in the rates of detoxiﬁcation in the series of the
OPs studied, different 6-OxP-CD and -CD concentrations had to
be used for the measurements. To allow comparison of the data,
pseudo second-order detoxiﬁcation constants kdetox were there-
fore calculated from the ratios of k1 and the corresponding CD
concentrations (Table 2).
Tables 1 and 2 show that the structure of the alcohol residue
on the OP affects detoxiﬁcation rate in a characteristic manner. In
addition, the substituted CD derivative 6-OxP-CD is a signiﬁcant
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Fig. 3. Time-dependent detoxiﬁcation mediated by -CD and 6-OxP-CD of n-
propylsarin as an example. (A) Aliquots, taken from an incubate of n-propylsarin
and 6-OxP-CD after 0–5 min, were transferred to a cuvette for measurement of the
inhibition kinetics with human AChE by an Ellman assay followed by non-linear
regression analysis for the determination of kobs; plots of kobs vs. the time at which
k1 was determined to calculate the ﬁrst-order rate constant for the detoxiﬁcation of
n-propylsarin by 6-OxP-CD (B) and -CD (C). Data shown in (B) and (C) are means
of  two  replicates ± the deviation of the two  measurements. Note the different time
scales in (B) and (C).
better scavenger than native -CD, independent of OP structure.
The oxime residue on the CD accelerates OP detoxiﬁcation over
the rate observed in the presence of -CD between a factor of 4.1
(for soman) and 98.8 (for cyclosarin). Table 2 shows that 6-OxP-
CD most effectively detoxiﬁes iso-pentylsarin and cyclosarin, while
the effect is approximately 100-fold lower in the case of soman
and sarin. A comparable pattern was  observed for the -CD medi-
ated detoxiﬁcation of these OPs although differences are markedly
lower.
2 Publications 9
212 A. Bierwisch et al. / Toxicology Letters 224 (2014) 209– 214
Table  1
First-order rate constants k1 describing the detoxiﬁcation rates corrected by the rates of spontaneous OP hydrolysis of the detoxiﬁcation of different sarin derivatives mediated
by  6-OxP-CD and -CD.
OP 6-OxP-CD k1 (min−1) -CD k1 (min−1) CD concentration (mM)
Ethylsarin 0.46 ± 0.04 0.002 ± 0.004 2.5
n-Propylsarin 0.96 ± 0.02 0.002 ± 0.002 2.5
Sarin  0.28 ± 0.02 0.004 ± 0.001 2.5
n-Butylsarin 3.24 ± 0.37 0.044 ± 0.007 2.5
iso-Butylsarin 2.51 ± 0.06 0.039 ± 0.003 2.5
n-Pentylsarin 1.98 ± 0.24 0.031 ± 0.005 0.5
iso-Pentylsarin 5.92 ± 0.43 0.080 ± 0.001 0.5
sec-Pentylsarin 4.94 ± 0.28 0.041 ± 0.002 0.5
neo-Pentylsarin 4.32 ± 0.25 0.074 ± 0.002 0.5
Soman  0.25 ± 0.01 0.059 ± 0.004 2.5
Cyclosarin 5.56 ± 0.72 0.056 ± 0.001 0.5
All constants were determined by non-linear regression analysis of kobs vs. time. Data were obtained from duplicate runs and are given as means ± SD. Note that different CD
concentrations were used in the experiments with pentylsarin analogs and cyclosarin.
4. Discussion
The results of the present study indicate that the -CD deriva-
tive 6-OxP-CD has the ability to detoxify a series of different alkyl
methylphosphonoﬂuoridates albeit at markedly different rates.
This CD derivative therefore meets an important prerequisite for
the use of small molecule or enzyme-based scavengers, namely
to act against a variety of relevant and structurally different OPs
(Masson and Rochu, 2009).
In the case of CD-based scavengers it is generally assumed that
detoxiﬁcation involves initial incorporation of part of the OP into
the CD cavity, which brings a hydroxyl group or a nucleophilic
substituent on the ring in close proximity to the OP phospho-
rus atom (Van Hooidonk and Breebaart-Hansen, 1970; Desiré and
Saint-André, 1986; Desiré and Saint-André, 1987; Hoskin et al.,
1999; Wille et al., 2009; Le Provost et al., 2011; Müller et al., 2011;
Zengerle et al., 2011). Subsequent reaction between the CD and the
OP then leads to deactivation. For a given CD derivative such as
6-OxP-CD detoxiﬁcation rates should therefore depend on the sta-
bility of the complex formed between the CD and an OP as well
as on structural parameters of this complex. Thermodynamic sta-
bility determines the amount of complex in solution: the higher
stability, the more complex is present and the faster the reaction
between CD and OP. However, if the nucleophilic group on the CD
and the OP phosphorous atom are arranged in the complex formed
between the two  components in a fashion that does not easily allow
reaction, detoxiﬁcation rates are expected to be low even if a stable
complex is formed. In certain cases, CDs can even protect OPs from
being detoxiﬁed because the OP is protected in the CD complex
from reacting with water (Cruickshank et al., 2013).
Unfortunately, no information is available about the stabilities
of complexes between -CD and sarin derivatives. However, sta-
bilities have been determined for complexes between the alcohol
components of the sarin derivatives investigated in this work and
-CD (Rekharsky and Inoue, 1998). Since these sarin derivatives
differ only in the alcohol part, the corresponding alcohols could
be regarded as suitable analogs. A particularly useful study in this
respect is the one of the Matsui and Mochida (1979), in which inter-
actions between -CD and the whole set of alcohols underlying the
sarin derivatives investigated here were quantiﬁed under compa-
rable conditions. The stability constants reported in the work of
Matsui and Mochida are included in Table 2.
Table 2 shows that, indeed, sarin derivatives are generally detox-
iﬁed more rapidly if their alcohol component forms a more stable
complex with the -CD ring. This trend is independent of whether
the -CD is substituted or not. Matsui und Mochida assumed that
1-pentanol could ﬁt completely into the -CD cavity, which agrees
well with the fact that pentylsarin derivatives are detoxiﬁed most
rapidly, with the highest rates of detoxiﬁcation observed for iso-
pentylsarin. iso-Pentylsarin is detoxiﬁed even slightly faster than
what was  previously observed for cyclosarin (Zengerle et al., 2011).
While this trend supports the assumption that stability of
the complexes formed between these sarin derivatives and -CD
affects detoxiﬁcation rate there are also deviations. Most impor-
tantly, of all the sarin derivatives investigated soman is detoxiﬁed
with the lowest rate although the pinacolyl residue is expected
to efﬁciently interact with -CD. neo-Pentylsarin, which lacks the
methyl group at the carbon atom bound to the alcohol oxygen
with respect to soman, is detoxiﬁed considerably faster. In the
case of soman it is likely that structural parameters of the com-
plex (e.g. incomplete inclusion of the alcohol residue into the
CD cavity caused by steric effects of the methyl group next to
the oxygen atom) are responsible for inhibition of the reaction
between the phosphonate and a nucleophilic group on the ring.
In addition, one has to consider that soman exists as a mixture
of four stereoisomers of which the two P(−)  enantiomers have a
higher inhibitory potency toward AChE than the P(+) enantiomers
(De Jong et al., 1988). It cannot be ruled out that 6-OxP-CD mediated
Table 2
Second-order detoxiﬁcation constants kdetox of the detoxiﬁcation of different sarin derivatives mediated by 6-OxP-CD and -CD.
OP 6-OxP-CD kdetox × 10−2 (M−1 min−1) -CD kdetox × 10−2 (M−1 min−1) kdetox (6OxP-CD)/kdetox (-CD) log Kaa
Ethylsarin 1.8 ± 0.1 0.009 ± 0.015 211 −0.03
n-Propylsarin 3.8 ± 0.1 0.009 ± 0.005 418 0.57
Sarin  1.1 ± 0.1 0.017 ± 0.001 65 0.58
n-Butylsarin 13.0 ± 1.5 0.175 ± 0.029 74 1.22
iso-Butylsarin 10.0 ± 2.5 0.157 ± 0.011 64 1.62
n-Pentylsarin 39.7 ± 4.9 0.622 ± 0.100 64 1.80
iso-Pentylsarin 118.5 ± 8.6 1.591 ± 0.009 74 2.25
sec-Pentylsarin 98.9 ± 5.5 0.825 ± 0.044 120 2.08
neo-Pentylsarin 86.5 ± 5.0 1.483 ± 0.034 58 2.76
Soman 1.0 ± 0.1 0.237 ± 0.015 4 2.75
Cyclosarin 111.2 ± 14.4 1.125 ± 0.027 99 2.70
a Stability constants log Ka of the complexes between -CD and the corresponding alcohol component of the OP. Data taken from Matsui and Mochida (1979).
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detoxiﬁcation of the P(−)C(−)  and P(−)C(+) soman enantiomers
proceeds at signiﬁcantly different rates. Indeed, cyclosarin detoxiﬁ-
cation mediated by 6-OxP-CD is highly enantioselective indicating
that the absolute conﬁguration of the OP also has an inﬂuence on
the rates of OP deactivation (Zengerle et al., 2011).
The fact that 6-OxP-CD exhibits a substantially higher detoxiﬁ-
cation activity for all sarin derivatives studied in comparison with
native -CD is a strong indication that the nucleophilic oxime group
in 6-OxP-CD participates in the reaction. It should be noted that the
effect of the oxime group is smallest in the case of soman detoxiﬁca-
tion, which again suggests that the nucleophilic group in 6-OxP-CD
is not well positioned to efﬁciently react with this OP in contrast to
other sarin derivatives.
In conclusion, this systematic study indicates that there exists
a clear structure activity relationship in the 6-OxP-CD mediated
deactivation of sarin derivatives. Activities could be correlated with
the stability of the sarin complexes, but seem to be also inﬂuenced
by structural parameters of the complexes formed. The moder-
ate to high efﬁcacy of 6-OxP-CD on sarin detoxiﬁcation suggests
the potential applicability of this compound as a small molecule
scavenger for G-type nerve agents.
Conﬂict of interest
The concept and execution of the project, the interpretation of
the results, and the preparation of the manuscript were under the
control of the authors and have not been inﬂuenced by the German
Ministry of Defence.
Acknowledgment
This research was supported by a contract of the German Armed
Forces (E/UR2W/CF511/9A803). The generous funding is gratefully
acknowledged.
References
Aldridge, W.N., Reiner, E., 1972. Enzyme Inhibitors as Substrates-Interactions of
Esterases with Esters of Organophosphorus and Carbamic Acids. North-Holland
Publishing Company, Amsterdam, London.
Aurbek, N., Thiermann, H., Szinicz, L., Eyer, P., Worek, F., 2006. Analysis of
inhibition, reactivation and aging kinetics of highly toxic organophospho-
rus  compounds with human and pig acetylcholinesterase. Toxicology 224,
91–99.
Aurbek, N., Worek, F., Thiermann, H., 2009. Aktuelle Aspekte in der Behandlung der
phosphororganischen Vergiftung. Wehrmed. Mschr. 53, 340–349.
Bergeron, R.J., Channing, M.A., Gibeily, G.J., Pillor, D.M., 1977. Disposition
requirements for binding in aqueous solution of polar substrates in the cyclo-
hexaamylose cavity. J. Am.  Chem. Soc. 99, 5146–5151.
Bergeron, R.J., Pillor, D.M., Gibeily, G., Roberts, W.P., 1978. Thermody-
namics of cycloamylose-substrate complexation. Bioorg. Chem. 7,
263–271.
Brandhuber, F., Zengerle, M.,  Porwol, L., Tenberken, O., Thiermann, H., Worek, F.,
Kubik, S., Reiter, G., 2012. Detoxiﬁcation of tabun at physiological pH mediated
by  substituted -cyclodextrin and glucose derivatives containing oxime groups.
Toxicology 302, 163–171.
Connors, K.A., 1997. The stability of cyclodextrin complexes in solution. Chem. Rev.
97, 1325–1358.
Cruickshank, D.L., Rougier, N.M., Vico, R.V., Bourne, S.A., Buján, E.I., Caira, M.R., de
Rossi, R.H., 2013. Inclusion of the insecticide fenitrothion in dimethylated--
cyclodextrin: unusual guest disorder in the solid state and efﬁcient retardation
of  the hydrolysis rate of the complexed guest in alkaline solution. Beilstein J.
Org. Chem. 9, 106–117.
De Jong, L.P.A., Van Dijk, C., Benschop, H.P., 1988. Hydrolysis of the four stereoisomers
of  soman catalyzed by liver homogenate and plasma from rat, guinea pig and
marmoset, and human plasma. Biochem. Pharmacol. 37, 2939–2948.
Desiré, B., Saint-André, S., 1986. Interaction of soman with beta-cyclodextrin. Fun-
dam. Appl. Toxicol. 7, 646–657.
Desiré, B., Saint-André, S., 1987. Inactivation of sarin and soman by cyclodextrins in
vitro. Experientia 43, 395–397.
Dodge, J.T., Mitchell, C., Hanahan, D.J., 1963. The preparation and chemical char-
acteristics of hemoglobin-free ghosts of human erythrocytes. Arch. Biochem.
Biophys. 100, 119–130.
Ellman, G.L., Courtney, K.D., Andres Jr., V., Featherstone, R.M., 1961. A new and rapid
colorimetric determination of acetylcholinesterase activity. Biochem. Pharma-
col. 7, 88–95.
Eyer, P., Worek, F., Kiderlen, D., Sinko, G., Stuglin, A., Simeon-Rudolf, V., Reiner, E.,
2003. Molar absorption coefﬁcients for the reduced Ellman reagent: reassess-
ment. Anal. Biochem. 312, 224–227.
Eyer, P., Worek, F., 2007. Oximes. In: Marrs, T.C., Maynard, R.L., Sidell, F.R. (Eds.),
Chemical Warfare Agents: Toxicology and Treatment. John Wiley & Sons Ltd.,
Chichester, pp. 305–329.
Gelb, R.I., Schwartz, L.M., Cardelino, B., Fuhrman, H.S., Johnson, R.F., Laufer, D.A.,
1981. Binding mechanisms in cyclohexaamylose complexes. J. Am.  Chem. Soc.
103, 1750–1757.
Hoskin, F.C.G., Steeves, D.M., Walker, J.E., 1999. Substituted cyclodextrin as a model
for  a quad enzyme that hydrolyzes the nerve gas soman. Biol. Bull. 197,
284–285.
Hennrich, N., Cramer, F., 1965. Inclusion compounds. 18. The catalysis of the ﬁs-
sion of pyrophosphates by cyclodextrin. A model reaction for the mechanism of
enzymes. J. Am.  Chem. Soc. 87, 1121–1126.
Karalliedde, L., Szinicz, L., 2001. Management of organophosphorous com-
pound poisoning. In: Karalliedde, L., Feldman, S., Henry, J., Marrs, C.T.
(Eds.), Organophosphates and Health. Imperial College Press, London,
p. 257.
Le Provost, R., Wille, T., Louise, L., Masurier, N., Müller, S., Reiter, G., Renard, P.-
Y.,  Lafont, O., Worek, F., Estour, F., 2011. Optimized strategies to synthesize
-cyclodextrin-oxime conjugates as a new generation of organophosphate sca-
vengers. Org. Biomol. Chem. 9, 3026–3032.
Masson, P., Rochu, D., 2009. Catalytic bioscavengers against toxic esters, an alter-
native approach for prophylaxis and treatments of poisonings. Acta Naturae 1,
68–78.
Masurier, N., Estour, F., Froment, M.T., Lefèvre, B., Debouzy, J.C., Brasme, B., Masson,
P.,  Lafont, O., 2005. Synthesis of 2-substituted -cyclodextrin derivatives with
a  hydrolytic activity against the organophosphorylester paraoxon. Eur. J. Med.
Chem. 40, 615–623.
Matsui, Y., Mochida, K., 1979. Binding forces contributing to the association of
cyclodextrin with alcohol in an aqueous solution. Bull. Chem. Soc. Jpn. 52,
2808–2814.
Müller, S., Koller, M., Le Provost, R., Lafont, O., Estour, F., Wille, T., Thiermann, H.,
Worek, F., Reiter, G., 2011. In vitro detoxiﬁcation of cyclosarin (GF) by modiﬁed
cyclodextrins. Toxicol. Lett. 200, 53–58.
Reiter, G., Mikler, J., Hill, I., Weatherby, K., Thiermann, H., Worek, F.,
2008. Chromatographic resolution, characterisation and quantiﬁcation of VX
enantiomers in hemolysed swine blood samples. J. Chromatogr. B 873,
86–94.
Reiter, G., Mikler, J., Hill, I., Weatherby, K., Thiermann, H., Worek, F., 2011. Simulta-
neous quantiﬁcation of VX and its toxic metabolite in blood and plasma samples
and its application for in vivo and in vitro toxicological studies. J. Chromatogr. B
879, 2704–2713.
Rekharsky, M.V., Inoue, Y., 1998. Complexation thermodynamics of cyclodextrins.
Chem. Rev. 98, 1875–1918.
Szejtli, J., 1998. Introduction and general overview of cyclodextrin chemistry. Chem.
Rev. 98, 1743–1753.
Taylor, P., Radic, Z., Hosea, N.A., Camp, S., Marchot, P., Berman, H.A., 1995. Structural
basis for the speciﬁcity of cholinesterase catalysis and inhibition. Toxicol. Lett.
82–83, 453–458.
Tabushi, I., Kiyosuke, Y., Sugimoto, T., Yamamura, K., 1978. Approach to the
aspects of driving force of inclusion by -cyclodextrin. J. Am.  Chem. Soc. 100,
916–919.
Tenberken, O., Worek, F., Thiermann, H., Reiter, G., 2010. Development and
validation of a sensitive gas chromatography–ammonia chemical ionization
mass spectrometry method for the determination of tabun enantiomers in
hemolysed blood and plasma of different species. J. Chromatogr. B 878,
1290–1296.
Van Hooidonk, C., Breebaart-Hansen, J.C.A.E., 1970. Stereospeciﬁc reaction of iso-
propyl methyl-phosphonoﬂuoridate (sarin) with -cyclodextrin: a model for
enzyme inhibition. Recl. Trav. Chim. Pays-Bas 89, 289–299.
Van Hooidonk, C., Groos, C.C., 1970. Model studies for enzyme inhibition. Part II: The
stereospeciﬁc reaction of isopropyl p-nitrophenyl methylphosphonate with -
cyclodextrin in aqueous alkaline media. Recl. Trav. Chim. Pays-Bas 89, 845–856.
Wiener, S.W., Hoffman, R.S., 2004. Nerve agents: a comprehensive review. J. Inten-
sive Care Med. 19, 22–37.
Wille, T., Tenberken, O., Reiter, G., Müller, S., Le Provost, R., Lafont, O., Estour, F.,
Thiermann, H., Worek, F., 2009. Detoxiﬁcation of nerve agents by a substi-
tuted -cyclodextrin: application of a modiﬁed biological assay. Toxicology 265,
96–100.
Wille, T., Scott, C., Thiermann, H., Worek, F., 2013. Detoxiﬁcation of G- and V-
series nerve agents by the phosphotriesterase OpdA. Biocat. Biotrans. 30,
03–208.
Worek, F., Kirchner, T., Bäcker, M.,  Szinicz, L., 1996. Reactivation by various oximes
of  human erythrocyte acetylcholinesterase inhibited by different organophos-
phorus compounds. Arch. Toxicol. 70, 497–503.
Worek, F., Mast, U., Kiderlen, D., Diepold, C., Eyer, P., 1999. Improved determination
of  acetylcholinesterase activity in human whole blood. Clin. Chim. Acta 288,
73–90.
Worek, F., Reiter, G., Eyer, P., Szinicz, L., 2002. Reactivation kinetics of acetyl-
cholinesterase from different species inhibited by highly toxic organophos-
phates. Arch. Toxicol. 76, 523–529.
2 Publications 11
214 A. Bierwisch et al. / Toxicology Letters 224 (2014) 209– 214
Worek, F., Thiermann, H., Szinicz, L., Eyer, P., 2004. Kinetic analysis of
interactions between human acetylcholinesterase, structurally differ-
ent organophosphorus compounds and oximes. Biochem. Pharmacol. 68,
2237–2248.
Zengerle, M., Brandhuber, F., Schneider, C., Worek, F., Reiter, G., Kubik, S., 2011.
Highly efﬁcient cyclosarin degradation mediated by a -cyclodextrin deriva-
tive  containing an oxime-derived substituent. Beilstein J. Org. Chem. 7,
1543–1554.
2 Publications 12
2 Publications 13
2.2 Kinetic analysis of interactions of amodiaquine with
human cholinesterases and organophosphorus
compounds
A. Bierwisch, T. Wille, H. Thiermann, F. Worek, Toxicology Letters 2016, 246, 49-56.
Reproduced by permission of Elsevier.
Inefficacy of oximes against several OP resulted in investigation of small molecules as
potential non-oxime reactivators. While performing in silico screening of databases,
several research groups identified new potential non-oxime reactivators. Among the
candidates, amodiaquine was most auspicious and in fact reactivated PXE-inhibited
AChE. Unfortunately, closer investigations were not pursued. Therefore in this study,
firstly interactions of amodiaquine with human AChE and BChE were investigated
and secondly with nerve agents in regard to its potential as a non-oxime reactivator.
All data was determined spectrophotometrically by a modified Ellman assay. Amodi-
aquine is a reversible inhibitor of human cholinesterases with a higher inhibitory
potency towards AChE (IC50 = 0.67 ± 0.02 µM) than BChE (IC50 = 81.28 ±
0.04 µM) (publication 2.2, Fig. 2). Determination of inhibition type was achieved
by performing Michaelis-Menten kinetics and Lineweaver-Burk plot (publication
2.2, Fig. 3) and revealed a mixed competitive-non-competitive inhibition type of
amodiaquine with AChE. As shown in figures 4 and 5 (publication 2.2) reactivation of
tabun-inhibited cholinesterases by amodiaquine was insufficient, however, cyclosarin-,
sarin-, and VX-inhibited cholinesterases were slowly and partially reactivated. Fur-
thermore, prophylactic administration of amodiaquine prior to soman poisoning
was tested in a dynamic model. Unfortunately, a protective effect or increased
reactivation of cholinesterases was not observed (publication 2.2, Table 2). Thus, it
can be concluded that administration of amodiaquine in vivo is unlikely due to its
high inhibitory potency towards cholinesterases. However, the findings indicate that
newly synthesized non-oxime reactivators could be based on amodiaquine’s structure
in order to increasing reactivation potency.
Kinetic analysis of interactions of amodiaquine with human
cholinesterases and organophosphorus compounds
Anne Bierwisch, Timo Wille, Horst Thiermann, Franz Worek*
Institut für Pharmakologie und Toxikologie der Bundeswehr, Neuherbergstraße 11, 80937 München, Germany
H I G H L I G H T S
 We investigated the interaction of human cholinesterases, OP nerve agents and amodiaquine.
 Amodiaquine is a potent inhibitor of human AChE and to less extent of human BChE.
 Amodiaquine resulted in slow and partial reactivation of sarin-, cyclosarin- and VX-inhibited AChE and BChE.
 Amodiaquine may be considered as a template for further non-oxime reactivators.
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A B S T R A C T
Standard therapy of poisoning by organophosphorus compounds (OP) is a combined administration of an
anti-muscarinic drug (e.g. atropine) and an oxime as reactivator of inhibited acetylcholinesterase (AChE).
Limited efﬁcacy of clinically used oximes against a variety of OPs was shown in numerous studies, calling
for research on novel reactivators of OP-inhibited AChE. Recently, reactivation of OP-inhibited AChE by
the antimalarial drug amodiaquine was reported. In the present study, amodiaquine and its interactions
with human cholinesterases in presence or absence of OP nerve agents was investigated in vitro. Thereby,
reversible inhibition of human cholinesterases by amodiaquine (AChE  BChE) was observed.
Additionally, a mixed competitive-non-competitive inhibition type of amodiaquine with human AChE
was determined. Slow and partial reactivation of sarin-, cyclosarin- and VX-inhibited cholinesterases by
amodiaquine was recorded, amodiaquine failed to reactivate tabun-inhibited human cholinesterases.
Amodiaquine, being a potent, reversible AChE inhibitor, was tested for its potential beneﬁt as a
pretreatment to prevent complete irreversible AChE inhibition by the nerve agent soman. Hereby,
amodiaquine failed to prevent phosphonylation and resulted only in a slight increase of AChE activity
after removal of amodiaquine and soman. At present the molecular mechanism of amodiaquine-induced
reactivation of OP-inhibited AChE is not known, nevertheless amodiaquine could be considered as a
template for the design of more potent non-oxime reactivators.
ã 2016 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Since their discovery in the mid-1930s, highly toxic nerve
agents have been deployed several times for example in civil war in
Iraq, terrorist attacks in Tokyo or most recently in Syria (Eisenkraft
et al., 2014; Macilwain, 1993; Nagao et al., 1997; UN Mission to
Investigate Allegations of the Use of Chemical Weapons in the
Syrian Arab Republic, 2013). Still, large stock piles of nerve agents
are available despite being banned by the Chemical Weapons
Convention (Organisation for the Prohibition of Chemical Weap-
ons, 1997) and easy access to open source literature on synthetic
routes (Holmstedt,1951) are reasons why nerve agents still pose an
ongoing threat.
Belonging to the superclass of organophosphorus compounds
(OP), nerve agents exert their acute toxicity through irreversible
inhibition of acetylcholinesterase (AChE; EC 3.1.1.7) by phosphy-
lation (denotes phosphorylation and phosphonylation) of the
serine hydroxyl group in its catalytic site (Marrs, 1993). Inhibited
AChE is incapable of hydrolyzing ACh resulting in an excess of ACh
at muscarinic (bradycardia, diarrhea, profuse sweating, salvation,
miosis, bronchorrhoea, bronchoconstriction) and nicotinic (con-
vulsions, muscle fasciculation, muscle dysfunction) receptors,
* Corresponding author. Fax: +49 89 992692 2333.
E-mail address: franzworek@bundeswehr.org (F. Worek).
http://dx.doi.org/10.1016/j.toxlet.2016.02.004
0378-4274/ã 2016 Elsevier Ireland Ltd. All rights reserved.
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eventually resulting in death by respiratory failure (Grob, 1956;
Holmstedt, 1959). The current standard therapy consists of
administration of a muscarinic antagonist (e.g. atropine) and an
oxime that functions as a reactivator of inhibited AChE (Lee, 2003;
Thiermann et al., 2013; Volans, 1996). Today, obidoxime, pralidox-
ime (2-PAM), and trimedoxime (TMB-4) are used clinically in OP
poisoning. Limited efﬁcacy of atropine-oxime combinations as
standard treatment against different nerve agents, e.g. soman,
tabun, and cyclosarin, has been shown in numerous in vitro and in
vivo studies (Dawson, 1994; Eyer et al., 2007; Lundy et al., 1992;
Marrs et al., 2006; Worek and Thiermann, 2013). Therefore, a vast
number of novel oximes have been synthesized by various research
groups so as to ﬁnd more effective reactivators, mainly focusing on
oximes that are effective against reactivation-resistant OP-AChE
complexes or a broad-spectrum of OP nerve agents (Bismuth et al.,
1992; Eyer and Worek, 2007; Hobbiger, 1963). Structure-activity
studies identiﬁed a small number of promising bispyridinium
oximes (Gray, 1984; Musilek et al., 2011; Schoene, 1980; Worek
et al., 2012). However, despite extensive research for decades, no
oxime that overcomes mentioned disadvantages has been discov-
ered.
Consequently, research started focusing on non-oxime reac-
tivators, which have preferential low toxicity, high blood-brain
barrier penetration, efﬁcacy against reactivation-resistant OP-
AChE complexes and a broad-spectrum against different OP nerve
agents. To identify a suitable non-oxime reactivator, Bhattacharjee
and co-workers adopted an in silico strategy of pharmacophore
modeling (Bhattacharjee et al., 2015, 2012; Leach et al., 2010) and
used it for virtual screening databases. During the process several
non-oxime reactivators were discovered with one reactivator
being equally efﬁcient as 2-PAM against DFP-induced neuropa-
thology in an in vivo assay with guinea pigs (Bhattacharjee et al.,
2015, 2012). Recently, Katz et al. (2015) performed in silico
screening and investigated non-oxime reactivators, from which
amodiaquine showed reactivating potency with paraoxon-inhib-
ited AChE.
Amodiaquine has antimalarial and anti-inﬂammatory proper-
ties and is one of the few antimalarial drugs that are effective
against the severe malaria tropica (Love et al., 1953; Mackenzie,
1983; Pomeroy et al., 1959). Numerous studies were performed
investigating amodiaquine’s mode of action, mainly focusing on its
side effects and revealing that high doses of amodiaquine over a
longer period cause hepatotoxicity and agranulocytosis, therefore
prophylactic administration is impossible (Booth et al., 1967; Glick,
1957; Hatton et al., 1986; Neftel et al., 1986). Our investigation
focused on interactions between amodiaquine and human AChE
and butyrylcholinesterase (BChE) in presence and absence of OP
nerve agents in vitro in order to evaluate the potential of
amodiaquine as non-oxime reactivator.
2. Materials and methods
2.1. Materials
Acetylthiocholine iodide (ATCh), amodiaquine dihydrochloride
dihydrate (AQ), S-butyrylthiocholine iodide (BTCh), 5,50-dithio-
bis-2-nitrobenzoic acid (DTNB, Ellman’s reagent), isolated human
butyrylcholinesterase (BChE, EC 3.1.1.8), and tris(hydroxymethyl)
aminomethane (Tris) were purchased from Sigma–Aldrich (Tauf-
kirchen, Germany). Disodium hydrogenphosphate dihydrate,
hydrochloride acid and potassium dihydrogenphosphate were
obtained from Carl Roth (Karlsruhe, Germany). HI-6 dichloride
monohydrate was provided by Dr. Clement (Defence Research
Establishment Sufﬁeld, Ralston, Alberta, Canada). Millex1-GS
0.22 mM particle ﬁlters were supplied by Millipore (Eschborn,
Germany).
O-Ethyl-S-2-diisopropylaminoethylmethylphosphonothiolate
(VX), tabun (GA), sarin (GB), cyclosarin (GF), and soman (GD) (>95%
by GC–MS, 1H NMR and 31P NMR) (Fig. 1) were made available by
the German Ministry of Defence (Bonn, Germany). All other
chemicals were from Merck Eurolab GmbH (Darmstadt, Germany)
at the purest grade available.
Stock solutions of tabun, sarin, cyclosarin, soman and VX (0.1%
v/v) were prepared in acetonitrile, stored at room temperature, and
diluted appropriately in either phosphate (0.1 M, pH 7.4) or
Tris–HCl buffer (0.1 M, pH 7.4) depending on further experiments.
Amodiaquine stock solution (50 mM) was prepared in distilled
water, stored at 80 C and diluted as required in distilled water
prior to use.
2.2. Preparation of hemoglobin-free erythrocyte ghosts
Hemoglobin-free erythrocyte ghosts served as source of human
erythrocyte acetylcholinesterase (AChE) and were prepared
according to Dodge et al., 1963 with minor modiﬁcations (Worek
et al., 2002). Brieﬂy, heparinized human whole blood (donated by
AB and FW) was centrifuged (3000  g,10 min) for plasma removal.
The erythrocytes were washed three times with two volumes of
phosphate buffer (0.1 M, pH 7.4). In order to facilitate hemolysis,
the packed erythrocytes were diluted in 20 volumes of hypotonic
phosphate buffer (6.7 mM, pH 7.4) and centrifuged at 50,000  g
(30 min, 4 C). After two additional washing cycles the pellet was
re-suspended in phosphate buffer (0.1 M, pH 7.4) and the initial
AChE activity was adjusted. Aliquots of erythrocyte ghosts were
stored at 80 C. Prior to use, thawed erythrocyte ghosts were
homogenized on ice with a Sonoplus HD 2070 ultrasonic
homogenisator (Bandelin electronic, Berlin, Germany) twice for
5 s with a 20 s interval in between to achieve a homogenous matrix
for kinetic studies.
2.3. Inhibition of AChE and BChE by amodiaquine
AChE or BChE and amodiaquine (0.1–500 mM) were added to
polystyrol cuvettes containing DTNB (0.5 mM) as chromogen and
ATCh (0.71 mM) or BTCh (1.58 mM) as substrate in 0.1 M phosphate
buffer. Enzyme activities were determined spectrophotometrically
(Cary 50 Bio, Varian, Darmstadt) at 412 nm for 1 min with a
Fig. 1. Chemical structures of amodiaquine and organophosphorus compounds.
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modiﬁed Ellman assay (Ellman et al., 1961; Eyer et al., 2003; Worek
et al., 1999). As a correction, measurements were performed
against a reference cuvette lacking enzymes. Experiments were
performed in duplicate and data were analyzed by non-linear
regression. All experiments were performed at 37 C and given
concentrations refer to ﬁnal concentrations.
2.4. Calculation of IC50
IC50 values were calculated from semi-logarithmic plots of
amodiaquine concentration versus enzyme activity (AChE or
BChE).
2.5. Reversibility of AChE inhibition by amodiaquine
Investigation of reversibility of AChE inhibition by amodiaquine
was carried out as followed: 200 mL AChE (37 C) were incubated
with 2 mL amodiaquine (5 mM f.c.) or distilled water as control.
After 5 min, an aliquot (50 mL) was transferred into 0.1 M
phosphate buffer (15 mL; 37 C), mixed and incubated for 5 min.
Afterwards, 3 mL incubate were transferred into a polystyrol
cuvette containing DTNB (0.3 mM) and ATCh (0.45 mM) and the
activity was measured at 412 nm for 3 min.
2.6. Determination of inhibition type of amodiaquine
To determine the inhibition type of amodiaquine, various ATCh
concentrations (5–200 mM) in absence or presence of amodiaquine
(0, 50, 100, and 200 nM) were added to polystyrol cuvettes (37 C)
containing AChE and DTNB (0.3 mM) and AChE activity was
measured at 412 nm for 2 min. Experiments were performed in
duplicate, recorded AChE activity was plotted vs. ATCh concen-
trations (Michaelis–Menten plot) and analyzed by non-linear
regression. Linearization of data by plotting 1/v vs. 1/[S] was
performed to obtain Lineweaver–Burk plots. Kinetic constants Km
and vmax were determined and used for distinguishing amodia-
quine’s inhibition type. Furthermore, two secondary re-plots of the
Lineweaver–Burk plot were generated by plotting slope and
ordinate intercepts of these lines vs. ligand concentration. From
X-intercepts of straight lines, inhibition constants kic (slope vs.
inhibitor concentration) and kiu (ordinate vs. inhibitor concentra-
tion) were determined and a was calculated from ratio (kiu/kic)
indicating the inhibitor’s inﬂuence on binding afﬁnity of enzyme to
substrate (Bisswanger, 1979).
2.7. Reactivation kinetics of OP-inhibited AChE or BChE by
amodiaquine
OP-inhibited enzymes were prepared by adding a small volume
(<1% v/v) of tabun, sarin, cyclosarin, and VX to AChE or BChE,
followed by incubation for 15 min at 37 C in order to achieve an
inhibition of >95% of control activity. For removal of excess OP,
inhibited samples were dialyzed in phosphate buffer (0.1 M, pH
7.4) overnight at 4 C and residual enzyme activity was measured
by incubation of OP-treated and control enzyme (30 min, 37 C).
Until use, aliquots were stored at 80 C.
150 mL OP-treated enzyme was mixed with equal volume of
phosphate buffer (0.1 M, pH 7.4) (containing 0.2% gelatin for
stabilizing AChE) and at t = 0, 3 mL amodiaquine were added to
initiate reactivation. After speciﬁed time intervals (t = 2–60 min),
aliquots were transferred to cuvettes containing phosphate buffer,
DTNB (0.3 mM) and ATCh (0.45 mM) or BTCh (1 mM) for
measurement of enzyme activity at 412 nm for 3 min. Three
different amodiaquine concentrations (1, 10, and 100 mM f.c.) were
used in the experiments (n = 2 independent experiments).
% reactivation was calculated by applying Eq. (1)
%reac ¼ ðA1  AiÞðA0  AiÞ
ð1Þ
with A0 control enzyme activity, Ai OP-inhibited enzyme activity,
and A1 amodiaquine reactivated enzyme activity. The ﬁrst order
reactivation rate constants (kobs) were determined by non-linear
regression analysis.
2.8. Reactivation kinetics of OP-inhibited AChE by amodiaquine and
HI-6
OP-inhibited AChE was mixed with equal volume of phosphate
buffer (0.1 M, pH 7.4) containing 0.2% gelatin, HI-6 (50 mM) and
amodiaquine (10 mM, t = 0) were added to initiate reactivation.
After speciﬁed time intervals (t = 2–60 min), aliquots were
transferred to cuvettes containing phosphate buffer, DTNB
(0.3 mM) and ATCh (0.45 mM) for measurement of enzyme activity
at 412 nm for 1 min. OP-inhibited enzyme activity and enzyme
activity after time-dependent reactivation was referred to control
enzyme activity and % reactivation was calculated thereof.
Experiments were performed in duplicate.
2.9. Determination of detoxiﬁcation constants
To investigate detoxiﬁcation kinetics of different OPs by
amodiaquine, an AChE inhibition assay was used. Therefore,
150 mL amodiaquine were mixed with 75 mL Tris–HCl (0.1 M, pH
7.4) and 75 mM OP (235 nM sarin, 40 nM cyclosarin, and 80 nM VX
f.c.). Amodiaquine concentration was 0.5 equimolar of the
respective OP concentration. After speciﬁed time intervals
(t = 0–60 min), aliquots were transferred to pre-heated cuvettes
(37 C) containing phosphate buffer, DTNB (0.3 mM) and ATCh
(0.75 mM) for recording the progressive inhibition of AChE at
436 nm for 5 min (n = 4).
Detoxiﬁcation constants were determined according to
Bierwisch et al. (2014). In brief, ﬁrst order inhibition rate constant
was calculated by analyzing recorded inhibition curves by non-
linear regression analysis. Inhibition rate constants were plotted
vs. incubation time. By ﬁtting the resulting decay curves, ﬁrst order
detoxiﬁcation constants k1 were obtained. k1 was corrected for the
spontaneous hydrolysis of the corresponding OP. Finally, half-lives
were calculated on the basis of Eq. (2).
t1=2 ¼ ln 2k1 ð2Þ
2.10. Dynamic model—general experimental procedure
For the online analysis of AChE activity, the well published
dynamic model (Eckert et al., 2006a,b) was used. In brief, 80 mL
human erythrocytes were diluted in 5 mL phosphate buffer (0.1 M,
pH 7.4) and subsequently 4.5 mL were layered onto a particle ﬁlter
(Millex1-GS, 0.22 mM, Ø 33 mm) with a peristaltic pump within
14 min. The AChE loaded enzyme reactor was submerged into a
water bath (`37 C, t = 0 min) and perfused with phosphate buffer
(0.1 M, pH 7.4). Continuous perfusion of enzyme reactor with ATCh
(0.45 mM), DTNB (0.3 mM), and phosphate buffer (0.1 M, pH 7.4)
was started at t = 15 min to measure control AChE activity
(t = 30 min). The total ﬂow rate through the reactor was
0.5 mL/min with the efﬂuent passing a photometer (LaChrom
L-7420 UV–vis detector, Merck, Darmstadt, Germany) set at
470 nm. In 1.6 s intervals absorbance values were collected.
The setup of the perfusion system consist of two HPLC pumps
with integrated quaternary low-pressure gradient formers
A. Bierwisch et al. / Toxicology Letters 246 (2016) 49–56 51
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(LaChrom L-1700, Merck), controlled by D-7000HPLC system
manager software (Vers. 4.1, Merck).
2.11. Perfusion protocol for inhibition and reactivation of AChE by
soman and amodiaquine
- Inhibition by GD: The enzyme reactor was perfused with 22 nM
GD from 60 to 90 min.
- Perfusion with amodiaquine and GD: The enzyme reactor was
perfused with 100 nM amodiaquine (t = 30 – 100 min) and with
22 nM GD from 60 to 90 min.
The recorded absorbance values were referred to the maximum
AChE activity in order to calculate the % inhibition and %
reactivation. Data are presented as means of four individual
experiments per group.
2.12. Data analysis
Kinetic constants were calculated from experimental data by
linear or non-linear regression analysis using Prism 5.04 (Graph-
Pad Software, San Diego, CA, USA). Data are presented as
means  SD and number of experiments n.
3. Results
3.1. Inhibition of AChE and BChE by amodiaquine
Enzyme activities were measured with different amodiaquine
concentrations to determine the inhibition of cholinesterases.
Amodiaquine resulted in complete inhibition of AChE activity
already at 20 mM while only an incomplete inhibition of BChE was
recorded with 500 mM amodiaquine (Fig. 2). This difference is
reﬂected by the calculated IC50 values of 669 nM with AChE
(R2 = 0.99) and 81 mM with BChE (R2 = 0.94).
The reversibility of AChE inhibition by amodiaquine was
investigated by inhibiting AChE with 5 mM amodiaquine followed
by extensive dilution (300-fold) and determination of enzyme
activity. A complete recovery of AChE activity was recorded
indicating reversible inhibition by amodiaquine.
3.2. Determination of inhibition type of amodiaquine
The inhibition type of amodiaquine was investigated by analysis
of AChE activities at different substrate and amodiaquine concen-
trations. As by deﬁnition, a classical non-competitive inhibitor has
a decreasing vmax and constant Km value by increasing inhibitor
concentrations and an intersection point on the abscissa of the
Lineweaver–Burk plot. Therefore, generated Michaelis–Menten
and double reciprocal Lineweaver–Burk plots (Fig. 3) with an
intersection within the second quadrant and to the left of the
ordinate indicate that amodiaquine is a mixed competitive-non-
competitive inhibitor of AChE. Additionally, kic and kiu values were
obtained from secondary re-plots of the Lineweaver–Burk plot and
a calculated from the ratio of kiu/kic, which was 1.45. An a
value > 1 implies an intersection above the abscissa and also
conﬁrms a mixed competitive-non-competitive inhibition type of
amodiaquine.
3.3. Reactivation kinetics of OP-inhibited AChE and BChE by
amodiaquine
Reactivation of tabun-, sarin-, cyclosarin-, and VX-inhibited
AChE and BChE by amodiaquine was determined with 1, 10 and
100 mM amodiaquine. The slow and partial reactivation of
OP-inhibited AChE and BChE by amodiaquine decreased in the
order VX > GF = GB while tabun-inhibited cholinesterases could not
be reactivated at all (Fig. 4 and 5). Reactivation of BChE was strictly
concentration-dependent while with AChE an increase of the
amodiaquine concentration from 10 to 100 mM resulted in a
decreased level of reactivation. This may be attributed to the high
inhibitory potency of amodiaquine with AChE. In fact, the residual
amodiquine concentration during the AChE assay (0.6 mM at
100 mM incubation concentration) results in substantial AChE
inhibition (cf. Fig. 2).
Additionally, the potential synergistic effect of amodiaquine
and HI-6 was investigated with OP-inhibited AChE. In presence of
10 mM amodiaquine, the velocity and extent of reactivation by
50 mM HI-6 was reduced moderately (data not shown).
3.4. Determination of detoxiﬁcation constants
Amodiaquine was incubated with a twofold excess of OP and
the time-dependent effect on AChE inhibition was determined.
From these data, calculation of detoxiﬁcation constants and half-
lives were performed. After correction for spontaneous hydrolysis
no detoxiﬁcation of tabun, sarin, cyclosarin and VX by amodia-
quine occurred.
3.5. Inhibition and reactivation of AChE by soman and amodiaquine
The ability of amodiaquine to protect human AChE from
irreversible inhibition by soman was investigated with the
dynamic model with real-time determination of enzyme activity.
Perfusion of enzyme reactors with 22 nM soman (t = 60–90 min)
resulted in rapid and virtually complete AChE inhibition (Fig. 6 and
Table 2). Perfusion of enzyme reactors with 100 nM amodiaquine
in the absence of soman (t = 30–60 min) resulted in an AChE
inhibition by 80% (Fig. 6). Additional perfusion with soman
(t = 60–90 min) induced complete inhibition (Table 2). Termination
of amodiaquine perfusion at t = 100 min resulted in a small
increase of AChE activity which was absent in the soman only
group (Fig. 6 and Table 2).
4. Discussion
The recent observation of partial reactivation of paraoxon-
inhibited AChE by the non-oxime amodiaquine (Katz et al., 2015)
prompted us to test the ability of amodiaquine to reactivate nerve
agent-inhibited human AChE and BChE and to investigate a
potential inhibitory potential of this compound with human
cholinesterases.
Fig. 2. Effect of amodiaquine on AChE and BChE activity. Various amodiaquine
concentrations (0.1–500 mM) were added to cholinesterases and residual enzyme
activity was measured. Data are shown as means  SD (n = 2).
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Antimalarial drugs, e.g. chloroquine, quinacrine, primaquine
(Wright and Sabine, 1948) and amodiaquine (Go et al., 1981) are
inhibitors of cholinesterases. The inhibitory activity of amodia-
quine was related to binding of its phenolic hydroxyl and
protonated diethylamino moiety or protonated quinolyl nitrogen
in the esteric and anionic site of AChE (Go et al., 1981). AChE
activity is fully regained after inhibition by amodiaquine, thus
being a reversible inhibitor. Calculated IC50 values characterize
amodiaquine as a highly potent inhibitor of human AChE whereas
its inhibitory potency was low with human BChE (Fig. 2). Poor
ﬁtting of amodiaquine into the BChE binding site may explain its
lower inhibitory potency with BChE. Due to a different composi-
tion of aromatic residues in human AChE and BChE, BChE has a
larger available space in its binding site, thus preferring binding of
larger substrates and inhibitors to its esteric or anionic site than
human AChE.
Generated Michaelis–Menten and Lineweaver–Burk plots and
thereof calculated vmax, and Kmvalues (Fig. 3) were used to identify
the inhibition type of amodiaquine. Decreasing Km and vmax values
in Michaelis–Menten plot, an intersection within the second
quadrant, above the abscissa with an a > 1 and to the left of the
ordinate of the Lineweaver–Burk plot indicate that amodiaquine is
as a mixed competitive-non-competitive inhibitor of human AChE.
The obtained mixed competitive-non-competitive inhibition type
of amodiaquine is in contrast to ﬁndings of Go et al. (1981), who
determined a competitive inhibition type for amodiaquine with
electric eel AChE.
In previous studies, therapeutic plasma levels of amodiaquine
in humans were determined to be less than 0.1 mM (Liu et al., 2014;
Orrell et al., 2008) which may give an explanation of the absence of
cholinergic side effects during the therapy with this antimalarial
drug.
Sarin-, cyclosarin- and VX-inhibited human AChE and BChE was
partially reactivated by amodiaquine, however at a slow rate
(Fig. 4 and 5). In comparison to the bispyridinium oxime
HI-6 amodiaquine was a substantially less potent reactivator of
nerve agent-inhibited human AChE (Table 1). The high intrinsic
inhibitory potency of amodiaquine with human AChE does not
allow the use of high amodiaquine concentrations. In fact,
incubation of OP-inhibited AChE with 100 mM amodiaquine
Fig. 3. Determination of inhibition type of amodiaquine by measuring substrate concentration-dependent curves of AChE activities with different amodiaquine
concentrations. The generated data were analyzed and plotted according to Michaelis–Menten (A) and Lineweaver–Burk (B). Experiments were performed in duplicate and
means  SD are shown.
Fig. 4. Kinetics of reactivation of AChE inhibited by tabun (A), sarin (B), cyclosarin (C) and VX (D) by various amodiaquine concentrations. The AChE activities are expressed as
% reactivation. Data are shown as means  SD (n = 2).
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resulted in a reduced apparent reactivation which was potentially
due to the inhibition of reactivated AChE by the residual
amodiaquine concentration (0.6 mM) during the AChE assay. In
comparison, a concentration-dependent increase of reactivation
was recorded with OP-inhibited BChE, most probably due to the
low inhibitory activity of amodiaquine with human BChE.
The underlying mechanism of reactivation of OP-inhibited
cholinesterases by amodiaquine has not been discovered yet. One
conceivable mechanism could be interaction of amodiaquine
within the active site and therefore being in close proximity to the
covalently bound serine, which is reactivated. Otherwise amodia-
quine, as a mixed competetive-non-competitive inhibitor, could
also interact with the peripheral anionic site (PAS) and generate
conditions in the active site were cleavage of OP-residue is
preferential and reactivation can occur.
Simultaneous incubation of OP-inhibited AChE with amodia-
quine (10 mM) and HI-6 (50 mM) resulted in a moderate decrease of
HI-6-induced reactivation. This may be attributed to a competition
of the highly potent AChE inhibitor amodiaquine with the oxime.
The ability of amodiaquine to reactivate nerve agent-inhibited
cholinesterases prompted us to investigate if amodiaquine could
detoxify these agents by binding or hydrolysis as was shown
previously with other small molecules (Bierwisch et al., 2014).
Unfortunately, incubation of amodiaquine with sarin, cyclosarin or
VX did not result in a reduction of AChE inhibition which indicates
that amodiaquine has no potential to serve as a small molecule
scavenger.
Previous studies showed that pretreatment of human AChE
with carbamates and the reversible AChE inhibitor huperzine A
protects the enzyme to some degree from irreversible phosphy-
lation by soman (Eckert et al., 2007, 2006b; Herkert et al., 2011,
2008). Hence, it was tempting to investigate whether the potent
AChE inhibitor amodiaquine would show a comparable effect.
Utilizing a dynamic model with real-time determination of AChE
activity allowed the online recording of inhibition and reactivation
kinetics in the presence of amodiaquine and soman. Preincubation
of AChE with amodiaquine (100 nM) resulted in approx. 80%
Fig. 5. Kinetics of reactivation of BChE inhibited by tabun (A), sarin (B), cyclosarin (C) and VX (D) by various amodiaquine concentrations. The BChE activities are expressed as
% reactivation. Data are shown as means  SD (n = 2).
Fig. 6. Inhibition and reactivation of human AChE with soman in presence or
absence of amodiaquine. Time-course of AChE activity following inhibition with
22 nM soman (GD; t = 60–90 min) or pre-treatment of 100 nM amodiaquine starting
at t = 30 min followed by 22 nM GD (t = 60–90 min). Amodiaquine perfusion was
terminated at t = 100 min (indicated by horizontal bars). Data are shown as means of
4 experiments as % of control.
Table 1
Reactivation of OP-inhibited AChE or BChE by amodiaquine. Reactivation rate
constants (kobs) were determined by non-linear regression analysis. Data are given
as means  SD (n = 2). Ø calculation of reactivation constant not possible due to
inadequate reactivation of inhibited AChE. For comparison, the corresponding kobs
values for HI-6 were included.
kobs [min1]
AChE BChE
10 mM AQ 10 mM HI-6a 100 mM AQ 100 mM HI-6b
GA Ø Ø Ø 0.0004
GB Ø 0.1128 0.0063 0.0265
GF Ø 0.2068 0.0069 0.1273
VX 0.0124 0.1126 0.0187 0.0190
a from Worek et al. (2004).
b from Aurbek et al. (2009).
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inhibition (Fig. 6), slowed down the subsequent inhibition by
soman (22 nM) but could not prevent complete inhibition of the
enzyme (Table 2). However, pretreatment of AChE with amodia-
quine resulted in a slight but signiﬁcant recovery of AChE activity
after termination of perfusion with amodiaquine and soman which
indicates the protection of a small portion of AChE from
phosphylation by soman. In comparison to huperzine A (33.7%),
as well as the carbamates pyridostigmine and physostigmine, the
extent of ﬁnal recovery of AChE activity was markedly lower with
amodiaquine (5.4%) at a comparable level of initial inhibition by
the reversible inhibitors (Eckert et al., 2007; Herkert et al., 2011,
2008). These data indicate that it is unlikely to consider
amodiaquine as a promising candidate for the pretreatment of
anticipated exposure to highly toxic nerve agents like soman.
In conclusion, the non-oxime amodiaquine proved to be a
reactivator of a broad spectrum of OP nerve agents although the
exact mechanism of action is not known. The high inhibitory
potency of amodiaquine towards human AChE is the major
limitation for its use in vivo. Nevertheless, the unexpected
potential of amodiaquine to reactivate OP-inhibited AChE makes
it a suitable template for the design of more effective non-oxime
reactivators with less intrinsic inhibitory activity towards human
AChE.
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